Overexpression of Kallikrein Gene 10 is a Biomarker for Predicting Poor Prognosis in Gastric Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Jan 11

PMID 24409072

Citations 12

Authors

Xin Jiao

Hong-Jun Lu

Mi-Mi Zhai

Zhi-Jun Tan

Hai-Ning Zhi

Xiao-Man Liu

Chen-Hao Liu

Da-Peng Zhang

Affiliations

Soon will be listed here.

Abstract

Aim: To analyze the expression of kallikrein gene 10 (KLK10) in gastric cancer and to determine whether KLK10 has independent prognostic value in gastric cancer.

Methods: We studied KLK10 expression in 80 histologically confirmed gastric cancer samples using real-time quantitative reverse transcription-PCR and hK10 expression using immunohistochemistry. Correlations with clinicopathological variables (lymph node metastasis, depth of invasion and histology) and with outcomes (disease-free survival and overall survival) during a median follow-up period of 31 mo were assessed. Gastric cancer tissues were then classified as KLK10 positive or negative.

Results: KLK10 was found to be highly expressed in 57/80 (70%) of gastric cancer samples, while its expression was very low in normal gastric tissues. Positive relationships between KLK10 expression and lymph node metastasis (P = 0.048), depth of invasion (P = 0.034) and histology (P = 0.015) were observed. Univariate survival analysis revealed that gastric cancer patients with positive KLK10 expression had an increased risk for relapse/metastasis and death (P = 0.005 and 0.002, respectively). Cox multivariate analysis indicated that KLK10 was an independent prognostic indicator of disease-free survival and overall survival in patients with gastric cancer.

Conclusion: KLK10 expression is an independent biomarker of unfavorable prognosis in patients with gastric cancer.

Citing Articles

HCMV detection in Asian gastric cancer RNA-seq data sets and clinical validation in Indian GC patients reveals the HCMV-GC specific gene signatures.

Krishnamoorthy P, Raj A, Das N, Chenkual S, Pautu J, Ralte L mSystems. 2024; 9(10):e0067324.

PMID: 39283078 PMC: 11494955. DOI: 10.1128/msystems.00673-24.

KLK10 derived from tumor endothelial cells accelerates colon cancer cell proliferation and hematogenous liver metastasis formation.

Kato K, Noda T, Kobayashi S, Sasaki K, Iwagami Y, Yamada D Cancer Sci. 2024; 115(5):1520-1535.

PMID: 38475666 PMC: 11093189. DOI: 10.1111/cas.16144.

Identification and validation of key genes associated with pathogenesis and prognosis of gastric cancer.

Li A, Li Y, Li Y, Zhang M, Zhang H, Chen F PeerJ. 2023; 11:e16243.

PMID: 37868053 PMC: 10586292. DOI: 10.7717/peerj.16243.

Prospective quantitative gene expression analysis of kallikrein-related peptidase as a diagnostic biomarker for childhood acute lymphoblastic leukemia.

Ahmad S, Ahmed B, Khidhir K, Rahman H PeerJ. 2022; 10:e13489.

PMID: 35669967 PMC: 9165590. DOI: 10.7717/peerj.13489.

miR‑3664‑5P suppresses the proliferation and metastasis of gastric cancer by attenuating the NF‑κB signaling pathway through targeting MTDH.

Jiao Y, Yang H, Qian J, Gong Y, Liu H, Wu S Int J Oncol. 2019; 54(3):845-858.

PMID: 30628643 PMC: 6365029. DOI: 10.3892/ijo.2019.4680.

References

Talieri M, Li L, Zheng Y, Alexopoulou D, Soosaipillai A, Scorilas A . The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer. 2009; 100(10):1659-65. PMC: 2696752. DOI: 10.1038/sj.bjc.6605033. View

Gratio V, Loriot C, Virca G, Oikonomopoulou K, Walker F, Diamandis E . Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. Am J Pathol. 2011; 179(5):2625-36. PMC: 3204030. DOI: 10.1016/j.ajpath.2011.07.016. View

Bayani J, Paliouras M, Planque C, Shan S, Graham C, Squire J . Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Mol Oncol. 2009; 2(3):250-60. PMC: 5527811. DOI: 10.1016/j.molonc.2008.07.001. View

Hollenberg M, Oikonomopoulou K, Hansen K, Saifeddine M, Ramachandran R, Diamandis E . Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem. 2008; 389(6):643-51. DOI: 10.1515/BC.2008.077. View

Feng B, Xu W, Zheng M, Ma J, Cai Q, Zhang Y . Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol. 2006; 21(10):1596-603. DOI: 10.1111/j.1440-1746.2006.04228.x. View

Kim H, Scorilas A, Katsaros D, Yousef G, Massobrio M, Fracchioli S . Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001; 84(5):643-50. PMC: 2363783. DOI: 10.1054/bjoc.2000.1649. View

Dasgupta S, Tripathi P, Qin H, Bhattacharya-Chatterjee M, Valentino J, Chatterjee S . Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. Oral Oncol. 2005; 42(3):306-16. DOI: 10.1016/j.oraloncology.2005.08.007. View

Gratio V, Beaufort N, Seiz L, Maier J, Virca G, Debela M . Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol. 2010; 176(3):1452-61. PMC: 2832164. DOI: 10.2353/ajpath.2010.090523. View

Yang L, Parkin D, Li L, Chen Y, Bray F . Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer. 2004; 90(11):2157-66. PMC: 2409509. DOI: 10.1038/sj.bjc.6601813. View

10.

Diamandis E, Yousef G . Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem. 2002; 48(8):1198-205. View

11.

Ramachandran R, Eissa A, Mihara K, Oikonomopoulou K, Saifeddine M, Renaux B . Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14. Biol Chem. 2012; 393(5):421-7. DOI: 10.1515/hsz-2011-0251. View

12.

Avgeris M, Papachristopoulou G, Polychronis A, Scorilas A . Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin Proteomics. 2011; 8(1):5. PMC: 3167201. DOI: 10.1186/1559-0275-8-5. View

13.

White N, Chow T, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H . Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer. 2010; 102(8):1244-53. PMC: 2856011. DOI: 10.1038/sj.bjc.6605634. View

14.

Yousef G, Borgono C, Scorilas A, Ponzone R, Biglia N, Iskander L . Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer. 2002; 87(11):1287-93. PMC: 2408908. DOI: 10.1038/sj.bjc.6600623. View

15.

Inoue Y, Yokobori T, Yokoe T, Toiyama Y, Miki C, Mimori K . Clinical significance of human kallikrein7 gene expression in colorectal cancer. Ann Surg Oncol. 2010; 17(11):3037-42. DOI: 10.1245/s10434-010-1132-y. View

16.

McCormack R, Rittenhouse H, Finlay J, Sokoloff R, Wang T, Wolfert R . Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995; 45(5):729-44. DOI: 10.1016/s0090-4295(99)80076-4. View

17.

Luo L, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Van Gramberen M . The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003; 63(4):807-11. View

18.

Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B . Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003; 63(11):2771-4. View

19.

Liu J, Chen L . Current status and progress in gastric cancer with liver metastasis. Chin Med J (Engl). 2011; 124(3):445-56. View

20.

Luo L, Diamandis E, Look M, Soosaipillai A, Foekens J . Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer. 2002; 86(11):1790-6. PMC: 2375391. DOI: 10.1038/sj.bjc.6600323. View